Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison

BACKGROUND: In schizophrenia, medication adherence is critical to achieve better patient outcomes and to avoid relapses, which are responsible for a significant proportion of total healthcare costs for this chronic illness. The aim of this study was to assess the cost-effectiveness of olanzapine lon...

Descripción completa

Detalles Bibliográficos
Autores principales: Dilla, Tatiana, Möller, Jörgen, O’Donohoe, Paul, Álvarez, María, Sacristán, José A, Happich, Michael, Tockhorn, Antje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268824/
https://www.ncbi.nlm.nih.gov/pubmed/25438678
http://dx.doi.org/10.1186/s12888-014-0298-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268824/
https://www.ncbi.nlm.nih.gov/pubmed/25438678
http://dx.doi.org/10.1186/s12888-014-0298-4

Ejemplares similares